It was a pleasure to speak with Sarah Van Tassel (Weill Cornell Medicine, NY, USA) on her thoughts about the new therapeutic options for glaucoma management and the promising new combinations on the horizon.
- How has the pharmaceutical landscape for glaucoma developed in the last year? (00:12)
- Where do rho-kinase inhibitors sit in the treatment paradigm for glaucoma? (02:17)
- What promising new drugs and combinations are in the pipeline? (03:46)
Speaker Disclosure: Sarah Van Tassel has received speaker’s fees from the following: Aerie, Allergan, Zeiss, New World Medical, Equinox Ophthalmic.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of Kiaweh Eye 2021.
